Adam Kittai, MD, breaks down the evolving landscape of CLL sequencing—from venetoclax retreatment to triplet regimens. As he ...
The sneaky virus poses serious health threats if it goes on to become a chronic disease. Clinical trial results suggest a new drug may cure 1 in 5 of those cases.
Progress against cancer doesn’t always arrive as headlines. Often, it shows up quietly in longer lives, better tolerability, ...
Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...
First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the ...
A newly approved combination of acalabrutinib plus venetoclax is giving people with newly diagnosed chronic lymphocytic leukemia (CLL) another chemotherapy-free option that is taken for a fixed period ...
Venetoclax plus acalabrutinib becomes the first fully oral, fixed-duration option for treatment-naïve CLL, adding a differentiated targeted approach to frontline regimen selection. A defined treatment ...
In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue their conversation on communicating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results